Investment Analysts’ Recent Ratings Changes for Ligand Pharmaceuticals (LGND)

Posted by on May 4th, 2026

A number of firms have modified their ratings and price targets on shares of Ligand Pharmaceuticals (NASDAQ: LGND) recently:

  • 5/1/2026 – Ligand Pharmaceuticals was upgraded by Weiss Ratings from “hold (c)” to “hold (c+)”.
  • 4/30/2026 – Ligand Pharmaceuticals had its price target raised by HC Wainwright from $243.00 to $289.00. They now have a “buy” rating on the stock.
  • 4/28/2026 – Ligand Pharmaceuticals had its price target raised by Royal Bank Of Canada from $235.00 to $252.00. They now have an “outperform” rating on the stock.
  • 4/15/2026 – Ligand Pharmaceuticals had its price target raised by Citigroup Inc. from $276.00 to $282.00. They now have a “buy” rating on the stock.
  • 4/14/2026 – Ligand Pharmaceuticals had its price target raised by HC Wainwright from $239.00 to $243.00. They now have a “buy” rating on the stock.
  • 3/24/2026 – Ligand Pharmaceuticals had its price target raised by Citigroup Inc. from $270.00 to $276.00. They now have a “buy” rating on the stock.
  • 3/11/2026 – Ligand Pharmaceuticals is now covered by Bank of America Corporation. They set a “buy” rating and a $244.00 price target on the stock.
  • 3/7/2026 – Ligand Pharmaceuticals was downgraded by Wall Street Zen from “buy” to “hold”.

Insider Activity at Ligand Pharmaceuticals

In other news, Director Stephen L. Sabba sold 2,034 shares of the stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $201.50, for a total value of $409,851.00. Following the completion of the transaction, the director owned 33,793 shares in the company, valued at $6,809,289.50. This trade represents a 5.68% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Andrew Reardon sold 5,000 shares of the business’s stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $206.35, for a total transaction of $1,031,750.00. Following the sale, the insider directly owned 36,869 shares in the company, valued at approximately $7,607,918.15. This represents a 11.94% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 30,448 shares of company stock worth $6,294,427. 7.00% of the stock is owned by company insiders.

Ligand Pharmaceuticals, Inc is a biopharmaceutical company that acquires, develops and out-licenses proprietary technologies designed to help pharmaceutical and biotechnology companies discover and develop novel medicines. Operating primarily through its research services and royalty-generating businesses, Ligand focuses on building a diversified portfolio of technology platforms and partnering with industry leaders to advance therapeutic candidates across multiple disease areas.

The company’s product offerings center around several core platforms.

Read More

Receive News & Ratings for Ligand Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.